Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. It develops solutions to preserving vision and improve eye health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. It also develops NCX 4251, an investigational ophthalmic treatment based on fluticasone propionate that is in Phase 2 clinical trial for the treatment of dry eye disease; and NCX 1728, a NO-donating phosphodiesterase-5 inhibitor, which is in preclinical evaluation. In addition, the company offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching related associated with allergic conjunctivitis. Nicox S.A. was founded in 1996 and is headquartered in Biot, France.
Frequently asked questions
What sector does NicOx S.A. (ALCOX) operate in?
NicOx S.A. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is NicOx S.A. (ALCOX) current stock price?
As of the latest data, NicOx S.A. stock price is €0.39, with a previous close of €0.39.
What is NicOx S.A. (ALCOX) current market capitalization?
NicOx S.A. market cap is approximately 37.58 million.
What is NicOx S.A. (ALCOX) Earnings Per Share (EPS)?
The trailing EPS is -€0.03, and the forward EPS is €0.01.
Does NicOx S.A. (ALCOX) pay dividends?
No. NicOx S.A. does not pay a dividend.
When is NicOx S.A. (ALCOX) next earnings report?
NicOx S.A. is expected to release its next earnings report on December 31, 2025.
What is NicOx S.A. (ALCOX) beta (volatility) score?
NicOx S.A. has a beta of 0.512, indicating lower volatility than the overall market.
